Kidney Disease Center, Zhejiang University School of Medicine First Affiliated Hospital; Institute of Nephrology, Zhejiang University; Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, Zhejiang, China.
Kidney Disease Center, Zhejiang University School of Medicine First Affiliated Hospital; Institute of Nephrology, Zhejiang University; Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, Zhejiang, China
Lupus Sci Med. 2021 Feb;8(1). doi: 10.1136/lupus-2020-000458.
To evaluate the performance of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis (LN) and their renal prognosis.
Patients with newly diagnosed SLE attending and followed up for >12 months were included. A retrospective review of all patients with renal biopsy fulfilling a consensus expert opinion during 2014 and 2018. Clinical, serological and pathological data were collected and each patient was assigned a high/low criteria scores (HS/LS) group. Survival curves for flare adjusted for multiplicity on renal flares, was applied to the two groups.
Applying EULAR/ACR criteria in our cohort of 126 patients, 6 (4.76%) did not meet the criterion, resulting in a sensitivity of 95.24%. The EULAR/ACR criteria scores was positively correlated with SLE disease activity index scores. Additionally, we noticed that a significant difference in clinical and immunological manifestations between HS and LS group. We observed a higher proportions of class Ⅲ or Ⅳ LN and lower proportions of class Ⅱ or V LN (p=0.034) and pathological higher activity index in HS group (p=0.007). Compared with LS groups, patients involved more severe renal damage and achieved higher rate of complete remission in the HS group. The Kaplan-Meier exploratory analyses, adjusted for LN classification, estimated glomerular filtration rate, activity index and chronicity index and induction and maintenance treatments, showed that patients in the HS group had a tendency of higher renal flare risk than that in the LS group (HR=0.21, p=0.04).
The EULAR/ACR criteria performed high sensitivity in identifying SLE in this cohort of biopsy-confirmed LN. Patients with LN with high criteria scores had more extrarenal manifestations, and worse renal prognosis in the short and long terms.
评估欧洲抗风湿病联盟/美国风湿病学会(EULAR/ACR)系统性红斑狼疮(SLE)分类标准在经活检证实的狼疮肾炎(LN)患者中的表现及其肾脏预后。
纳入新诊断为 SLE 并接受随访>12 个月的患者。对 2014 年和 2018 年期间所有满足共识专家意见的肾活检患者进行回顾性分析。收集临床、血清学和病理学数据,并为每位患者分配高/低标准评分(HS/LS)组。对肾发作进行多重调整后的发作调整生存曲线适用于两组。
在我们的 126 例患者队列中应用 EULAR/ACR 标准,有 6 例(4.76%)不符合标准,敏感性为 95.24%。EULAR/ACR 标准评分与 SLE 疾病活动指数评分呈正相关。此外,我们注意到 HS 和 LS 组之间在临床和免疫学表现上存在显著差异。我们观察到 HS 组中更常见的Ⅲ或Ⅳ级 LN,而较少见的Ⅱ或Ⅴ级 LN(p=0.034),且病理活动指数较高(p=0.007)。与 LS 组相比,HS 组患者的肾脏损害更为严重,完全缓解率更高。Kaplan-Meier 探索性分析,调整 LN 分类、估计肾小球滤过率、活动指数和慢性指数以及诱导和维持治疗,表明 HS 组患者的肾发作风险高于 LS 组(HR=0.21,p=0.04)。
在本活检证实的 LN 患者队列中,EULAR/ACR 标准对 SLE 的识别具有高敏感性。高标准评分的 LN 患者具有更多的肾外表现,且在短期和长期预后方面更差。